Skip to main content
OpenTrials
Completed

NCT Number: NCT01388088

The Effect of Amiloride and Spironolactone in Patients With Hypertension

The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone.

The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

45 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Medical Research

Holstebro, 7500, Denmark

About this study

Purpose of the study is to examine the effect of amilorid and spironolacton on

  • Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
  • Pulsewavevelocity, augmentation index and centralt bloodpressure,
  • Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
  • Ambulatory blood pressure

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertension
  • Age 45-70
  • BMI: 18,5-30

Exclusion criteria

  • Other diseases
  • Drug or alcohol abuse
  • Abnormal findings in the screening procedure

Treatment and study plan

Spironolactone

Drug

25 mg twice a day

Amiloride

Drug

5 mg twice a day

Placebo

Drug

twice a day

Primary outcomes

  1. Blood pressure

    Time frame: 2 years

    24 hours blood pressure measurements

Secondary outcomes

  1. Pulse wave velocity

    Time frame: 2 years

    We will investigate the changes in cardiovascular variables using a Sphygmocor scanner.

Sponsors and collaborators

Lead sponsor

Erling Bjerregaard Pedersen

Other

Registry information

Official study title

Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.

Acronym: hass

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jul 6, 2011
Registry last updated
Mar 28, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.